Optimizing carboplatin dosing using Computed Tomography derived body composition and serum creatinine

Optimizing carboplatin dosing using Computed Tomography derived body composition and serum creatinine - POPCORN study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON56726

Enrollment

Registered

2024-03-28

Start date

2024-12-13

Completion date

Unknown

Last updated

2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer ovarian cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age 18 years or older - Available contrast-enhanced enhanced CT-scan including L3 at baseline before carboplatin treatment (at least of six weeks before start of therapy)

Exclusion criteria

Exclusion criteria: - Conditions that affect hemostasis in a way that blood drawing is complicated (to be assessed by a physician) - Drugs that inhibit creatinine clearance in the kidneys, like cimetidine, trimethoprim, pyrimethamine, and salicylates (>100 mg) - A carboplatin target AUC of below 4 mg/mL*min

Design outcomes

Primary

Measure	Time frame
The covariate relationship between CT-derived body composition, serum creatinine, and carboplatin pharmacokinetics.	—

Secondary

Measure	Time frame
o The bias (Mean Percentage Error, MPE%), the imprecision (Mean Absolute Percentage Error, MAPE%) and the accuracy (Root Mean Squared Error, RMSE) of the predicted AUC versus the target AUC o The percentage of patients within 90-110% the target AUC will be assessed	—

Countries

Netherlands

Outcome results